Developer docs
API playgroundTry for free, no card

Search company profiles

Amneal Pharmaceuticals

Full company profile

uuid0000fbj

Namestring
Amneal Pharmaceuticals
Legal namestring
Amneal Pharmaceuticals, Inc.
Websiteurl
amneal.com
Company typeenum
Public
Founded yearint
2002
Descriptiontext

Amneal Pharmaceuticals, Inc. is a publicly traded U.S. pharmaceutical company (NASDAQ: AMRX) headquartered in Bridgewater, New Jersey, founded in 2002 by brothers Chirag and Chintu Patel. The company operates three reporting segments: Affordable Medicines (complex generics, injectables, and biosimilars spanning oral solids, ophthalmics, inhalation, topicals, transdermals, and nasal sprays); Specialty (branded CNS and endocrine products including CREXONT for Parkinson's disease and Brekiya for migraine and cluster headaches); and AvKARE (pharmaceutical distribution to U.S. federal government, retail, and institutional customers).

The company's technology foundation rests on proprietary drug delivery platforms including GRANDE® and KRONOTEC® for extended-release formulations, plus a novel mucoadhesive polymer technology used in CREXONT that delivers the longest-lasting levodopa plasma levels among oral carbidopa/levodopa therapies. Amneal operates approximately 1 million square feet of advanced U.S. manufacturing space in Brookhaven, NY, plus manufacturing operations in India (Ahmedabad, Vizag, Rajoda) and Ireland, supported by a global Quality organization of roughly 1,700 employees that has cleared 115+ regulatory inspections over 23 years.

Amneal generates revenue through product sales across 290+ medicines delivering 160+ million prescriptions annually. FY2025 net revenue was $3.02 billion (up 8% YoY) with FY2026 guidance of $3.05–$3.15 billion. Its go-to-market combines a direct field sales force, specialty pharmacy partnerships (Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy), U.S. wholesale distribution for generics, and direct federal distribution via the wholly-owned AvKARE subsidiary. Strategic partnerships include mAbxience for biosimilar development and commercialization (denosumab biosimilars Boncresa and Oziltus), KeifeRx for Parkinson's research collaboration, and a pending $1.1 billion acquisition of Kashiv BioSciences to build a fully integrated global biosimilars platform expected to close in H2 2026.

Short descriptiontext

Amneal Pharmaceuticals is a publicly traded U.S. biopharmaceutical company operating three segments: Affordable Medicines (generics, biosimilars, injectables), Specialty (branded CNS/endocrine therapies such as CREXONT and Brekiya), and AvKARE federal/institutional distribution, delivering 160+ million prescriptions annually across 290+ products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersBridgewater, United States
HQ citystring
Bridgewater
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, specialty medicines, biosimilar products, injectable manufacturing, pharmaceutical distribution
Industry4 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Biological Product (except Diagnostic) Manufacturing325414
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Ophthalmic Goods3851
Product category
Generic Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Affordable Medicines Segment
TypeOne Time License
Description

Revenue from generic pharmaceuticals including complex formulations, injectables, and biosimilars. This is the largest segment, covering retail and institutional products delivered through wholesalers and direct distribution.

investors.amneal.com
2Specialty Segment
TypeSubscription Recurring
Description

Revenue from branded pharmaceutical products focused on central nervous system (Parkinson's disease, migraine, cluster headache) and endocrine disorders. Commercialized through field sales force and specialty pharmacies.

investors.amneal.com
3AvKARE Segment
TypeTransaction Fee
Description

Distribution of pharmaceuticals and medical products to U.S. federal government, retail, and institutional customers.

investors.amneal.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details3 tiers
1CREXONT copay assistance program for commercially insured patients
ModelOtherBilling cadenceMonthly
Notes

Eligible commercially insured patients may qualify for a $25 copay on their prescriptions, applied automatically for most patients at the pharmacy through the CREXONT Savings Program.

investors.amneal.com
2Brekiya autoinjector copay program for commercially insured patients
ModelOtherBilling cadenceMonthly
Notes

Eligible commercially insured patients may pay as little as $40 per carton (4 single-dose autoinjectors per carton), applied automatically through the specialty pharmacy.

investors.amneal.com
3Patient Assistance Programs for underserved patients
ModelOtherBilling cadenceMonthly
Notes

Amneal provides patient assistance through Dispensary of Hope partnership, donating 20+ million dosages to low-income and uninsured patients. Additional patient assistance programs available for CREXONT and other specialty products.

amneal.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 12 records shown
1Amneal Biosciences
Description

Delivers growing portfolio of biosimilars and specialty injectable products

amneal.com
+11 more records
Core offering1 text field

Amneal Pharmaceuticals develops, manufactures, and commercializes generic pharmaceuticals, specialty branded medicines, and biosimilars across three segments: Affordable Medicines (complex generics, injectables, ophthalmics, inhalation products), Specialty (CNS and endocrine branded therapies for Parkinson's disease, migraine, cluster headache, and hypothyroidism), and AvKARE (pharmaceutical distribution to U.S. federal government, retail, and institutional markets). The company operates approximately 1 million square feet of advanced U.S. manufacturing space and delivers over 160 million prescriptions annually across its 290+ product portfolio.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 160+ million prescriptions delivered annually
+3 more records
Product overview1 text field

Amneal Pharmaceuticals operates as a diversified global biopharmaceutical company with three primary business segments: Affordable Medicines (generic and biosimilar products), Specialty (branded CNS and endocrine products), and AvKARE (pharmaceutical distribution). The Affordable Medicines segment includes over 270 generic medicines spanning complex formulations across oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, with key products including Beclomethasone Dipropionate HFA, epinephrine auto-injectors, and naloxone nasal spray. The Specialty segment features branded products including CREXONT (Parkinson's disease), Brekiya (migraine/cluster headache), RYTARY, UNITHROID, and ONGENTYS. The Biosciences portfolio includes biosimilar products FYLNETRA, ALYMSYS, Boncresa, and Oziltus, along with specialty injectables like Boruzu and PEMRYDI RTU. The company delivers over 160 million prescriptions annually across the U.S. market.

Product and service22 records
1CREXONT (carbidopa and levodopa)
CategorySpecialty Product
Description

Innovative extended-release oral formulation for Parkinson's disease combining immediate-release granules for rapid onset with extended-release pellets for long-lasting efficacy, providing longer Good On time with less frequent dosing.

2Brekiya (dihydroergotamine mesylate)
CategorySpecialty Product
Description

First and only ready-to-use dihydroergotamine (DHE) autoinjector approved for acute treatment of migraine with or without aura and acute treatment of cluster headaches in adults.

3RYTARY (carbidopa and levodopa)
CategorySpecialty Product
Description

Extended-release capsules for treatment of Parkinson's disease, providing continuous levodopa delivery.

4ONGENTYS (opicapone)
CategorySpecialty Product
Description

Capsules for treatment of Parkinson's disease as adjunct therapy to levodopa/carbidopa.

5UNITHROID (levothyroxine sodium)
CategorySpecialty Product
Description

Oral prescription medicine for hypothyroidism, providing thyroid hormone replacement.

6EMVERM (mebendazole)
CategorySpecialty Product
Description

Anthelmintic medication for treatment of worm infections including whipworm, hookworm, and pinworm.

7FYLBAR (filgrastim biosimilar)
CategoryBiosimilar
Description

Biosimilar referencing Neupogen for chemotherapy-induced neutropenia support.

8FYLNETRA (pegfilgrastim biosimilar)
CategoryBiosimilar
Description

Biosimilar to Amgen's Neulasta for reducing infection incidence in patients receiving myelosuppressive chemotherapy.

9ALYMSYS (bevacizumab biosimilar)
CategoryBiosimilar
Description

Biosimilar referencing Avastin for treatment of various cancers including metastatic colorectal cancer, non-small cell lung cancer, and renal cell carcinoma.

10Boncresa (denosumab biosimilar)
CategoryBiosimilar
Description

Biosimilar referencing Amgen's Prolia for osteoporosis treatment and bone loss prevention.

11Oziltus (denosumab biosimilar)
CategoryBiosimilar
Description

Biosimilar referencing Amgen's XGEVA for prevention of skeletal-related events in cancer patients with bone metastases.

12Boruzu (generic bortezomib)
CategorySpecialty Injectable
Description

Generic oncology injectable product for multiple myeloma treatment.

13PEMRYDI RTU
CategorySpecialty Injectable
Description

Ready-to-use oncology injectable developed via 505(b)(2) pathway, designed to simplify storage and preparation.

14Beclomethasone Dipropionate HFA Inhalation Aerosol
CategoryGeneric Respiratory Product
Description

FDA-approved generic equivalent for QVAR, available in 40 mcg and 80 mcg doses for asthma maintenance therapy in patients 5 years and older.

15Epinephrine Auto-injector
CategoryGeneric Emergency Product
Description

Auto-injector for emergency treatment of anaphylaxis.

16Naloxone HCl Nasal Spray
CategoryGeneric Emergency Product
Description

Opioid overdose reversal medication.

17Albuterol Sulfate Inhalation Aerosol
CategoryGeneric Respiratory Product
Description

Generic version of PROAIR HFA for treatment of bronchospasm.

18Cyclosporine Ophthalmic Emulsion 0.05%
CategoryGeneric Ophthalmic Product
Description

Generic version of RESTASIS for dry eye disease by increasing tear production.

19Iohexol Injection
CategoryGeneric Diagnostic Product
Description

Contrast agent for various imaging procedures including CT scans.

20Romidepsin Injection
CategoryGeneric Oncology Product
Description

Ready-to-use formulation for treating cutaneous T-cell lymphoma in adults who have received at least one prior systemic therapy.

21PATHways Patient Support Program
CategoryPatient Support Program
Description

Comprehensive patient and provider support program offering co-pay assistance, patient assistance, and treatment access support services.

22AvKARE Distribution Services
CategoryDistribution Services
Description

Distributor of pharmaceuticals and other products for U.S. federal government, retail, and institutional markets.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Definitive agreement for Amneal to acquire Kashiv BioSciences for $375M cash, $375M equity at closing, plus up to $350M in milestones (total $1.1B). The acquisition creates a fully integrated global biosimilars platform combining Kashiv's R&D, manufacturing, and regulatory capabilities with Amneal's commercial scale. Expected to close H2 2026 pending shareholder and regulatory approvals.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

Research collaboration and option agreement to advance pre-IND development of KFRX06, a preclinical candidate targeting Parkinson's disease based on KeifeRx's LRRK2 inhibitor technology. Collaboration establishes a structured path for potential next-stage development and commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Partnership for development and manufacturing of biosimilars. Amneal holds exclusive U.S. commercialization rights for jointly developed biosimilars including Boncresa and Oziltus (denosumab biosimilars referencing Prolia and XGEVA). mAbxience handles development and manufacturing while Amneal commercializes in the U.S.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-01-05
Description

Acquisition of Saol Therapeutics' Baclofen franchise including Lioresal and LYVISPAH products valued at approximately $83.5 million. Transaction aimed to expand Amneal's neurology portfolio and enhance biosimilar market entry.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-11-10
Description

Acquisition of Indian injectable drug manufacturer Puniska Healthcare for Rs 700 crore. Transaction expanded Amneal's injectable manufacturing capacity in the U.S. and globally, including India. Facility in Ahmedabad was prepared for USFDA inspection.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Twelve-year partnership with Nashville-based nonprofit distributing medicines to pharmacies and safety-net clinics for low-income, chronically ill patients. Amneal has donated more than 20 million dosages through this partnership, touching hundreds of thousands of lives across the U.S.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Largest U.S. generics manufacturer with a global specialty franchise (CNS, respiratory) and biosimilars pipeline. Direct head-to-head competitor with Amneal in U.S. generics and CNS specialty, including Parkinson's disease products; Amneal's former CCO (Andy Boyer) and Chief Legal Officer (Jason Daly) both came from Teva, underscoring competitive overlap.

TypeDirect peer
Description

Global generics and specialty pharma formed from Mylan and Upjohn. Competes directly with Amneal across U.S. generics, biosimilars, and select specialty categories, and is similarly exposed to U.S. generic pricing pressure and biosimilar launch cycles.

3Sandoz (Novartis)
TypeDirect peer
Description

Global leader in generics and biosimilars, now independent from Novartis. Competes directly with Amneal's Affordable Medicines and Biosciences segments, especially in biosimilars (denosumab, pegfilgrastim, bevacizumab) where Amneal is also launching. Jeff George (Amneal director) was previously CEO of Sandoz.

TypeDirect peer
Description

U.S./MENA generics and injectables manufacturer with a growing specialty franchise. Overlaps with Amneal's generics, injectables, and increasingly specialty footprint, including respiratory and CNS categories.

TypeDirect peer
Description

India-based global generics and biosimilars company with substantial U.S. presence. Competes with Amneal in complex generics, injectables, and biosimilars and shares a similar India-plus-US manufacturing cost structure.

6Sun Pharmaceutical Industries
TypeDirect peer
Description

India's largest specialty pharma company with a significant U.S. generics and specialty business (including CNS). Overlaps directly with Amneal's generic portfolio and U.S. specialty ambitions, particularly in neurology.

TypeDirect peer
Description

Indian-headquartered global generics and biosimilars manufacturer with strong U.S. share. Competes with Amneal across oral solids, injectables, and biosimilars, including respiratory and CNS categories.

TypeDirect peer
Description

India-based global pharma with a U.S. generics and specialty franchise (CNS, respiratory, women's health). Direct competitor with Amneal in U.S. complex generics and emerging biosimilars.

9Endo International
TypeEmerging player
Description

U.S. specialty and generics pharma with focus on neurology, pain, and ophthalmology. Overlaps with Amneal's specialty portfolio in CNS/neurology and shares exposure to U.S. specialty launch dynamics.

TypeRegional player
Description

India-based pharma with U.S. generics, injectables, and biosimilars business. Comparable to Amneal in manufacturing footprint and product mix; competes most directly in U.S. generics and biosimilars and shares similar India supply-chain dynamics. Several Amneal R&D and quality leaders previously worked at Zydus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles23 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amneal Pharmaceuticals

Generic Pharmaceuticalsamneal.com

Amneal Pharmaceuticals is a publicly traded U.S. biopharmaceutical company operating three segments: Affordable Medicines (generics, biosimilars, injectables), Specialty (branded CNS/endocrine therapies such as CREXONT and Brekiya), and AvKARE federal/institutional distribution, delivering 160+ million prescriptions annually across 290+ products.

What Amneal Pharmaceuticals does

Amneal Pharmaceuticals, Inc. is a publicly traded U.S. pharmaceutical company (NASDAQ: AMRX) headquartered in Bridgewater, New Jersey, founded in 2002 by brothers Chirag and Chintu Patel. The company operates three reporting segments: Affordable Medicines (complex generics, injectables, and biosimilars spanning oral solids, ophthalmics, inhalation, topicals, transdermals, and nasal sprays); Specialty (branded CNS and endocrine products including CREXONT for Parkinson's disease and Brekiya for migraine and cluster headaches); and AvKARE (pharmaceutical distribution to U.S. federal government, retail, and institutional customers).

The company's technology foundation rests on proprietary drug delivery platforms including GRANDE® and KRONOTEC® for extended-release formulations, plus a novel mucoadhesive polymer technology used in CREXONT that delivers the longest-lasting levodopa plasma levels among oral carbidopa/levodopa therapies. Amneal operates approximately 1 million square feet of advanced U.S. manufacturing space in Brookhaven, NY, plus manufacturing operations in India (Ahmedabad, Vizag, Rajoda) and Ireland, supported by a global Quality organization of roughly 1,700 employees that has cleared 115+ regulatory inspections over 23 years.

Amneal generates revenue through product sales across 290+ medicines delivering 160+ million prescriptions annually. FY2025 net revenue was $3.02 billion (up 8% YoY) with FY2026 guidance of $3.05–$3.15 billion. Its go-to-market combines a direct field sales force, specialty pharmacy partnerships (Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy), U.S. wholesale distribution for generics, and direct federal distribution via the wholly-owned AvKARE subsidiary. Strategic partnerships include mAbxience for biosimilar development and commercialization (denosumab biosimilars Boncresa and Oziltus), KeifeRx for Parkinson's research collaboration, and a pending $1.1 billion acquisition of Kashiv BioSciences to build a fully integrated global biosimilars platform expected to close in H2 2026.

Amneal Pharmaceuticals firmographics

Firmographics
Name
Amneal Pharmaceuticals
Legal name
Amneal Pharmaceuticals, Inc.
Website
https://amneal.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Amneal Pharmaceuticals is a publicly traded U.S. biopharmaceutical company operating three segments: Affordable Medicines (generics, biosimilars, injectables), Specialty (branded CNS/endocrine therapies such as CREXONT and Brekiya), and AvKARE federal/institutional distribution, delivering 160+ million prescriptions annually across 290+ products.
Ownership category
akta.pro rank

Amneal Pharmaceuticals industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Generic pharmaceuticals
  • Specialty medicines
  • Biosimilar products
  • Injectable manufacturing
  • Pharmaceutical distribution

Where Amneal Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Bridgewater
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Amneal Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Affordable Medicines Segment: Revenue from generic pharmaceuticals including complex formulations, injectables, and biosimilars. This is the largest segment, covering retail and institutional products delivered through wholesalers and direct distribution.
  2. Specialty Segment: Revenue from branded pharmaceutical products focused on central nervous system (Parkinson's disease, migraine, cluster headache) and endocrine disorders. Commercialized through field sales force and specialty pharmacies.
  3. AvKARE Segment: Distribution of pharmaceuticals and medical products to U.S. federal government, retail, and institutional customers.

Pricing tiers

ModelBillingPrice
OtherMonthlyCREXONT copay assistance program for commercially insured patients
OtherMonthlyBrekiya autoinjector copay program for commercially insured patients
OtherMonthlyPatient Assistance Programs for underserved patients

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Amneal Pharmaceuticals product offering

Product offering

Core offering

Amneal Pharmaceuticals develops, manufactures, and commercializes generic pharmaceuticals, specialty branded medicines, and biosimilars across three segments: Affordable Medicines (complex generics, injectables, ophthalmics, inhalation products), Specialty (CNS and endocrine branded therapies for Parkinson's disease, migraine, cluster headache, and hypothyroidism), and AvKARE (pharmaceutical distribution to U.S. federal government, retail, and institutional markets). The company operates approximately 1 million square feet of advanced U.S. manufacturing space and delivers over 160 million prescriptions annually across its 290+ product portfolio.

Product overview

Amneal Pharmaceuticals operates as a diversified global biopharmaceutical company with three primary business segments: Affordable Medicines (generic and biosimilar products), Specialty (branded CNS and endocrine products), and AvKARE (pharmaceutical distribution). The Affordable Medicines segment includes over 270 generic medicines spanning complex formulations across oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, with key products including Beclomethasone Dipropionate HFA, epinephrine auto-injectors, and naloxone nasal spray. The Specialty segment features branded products including CREXONT (Parkinson's disease), Brekiya (migraine/cluster headache), RYTARY, UNITHROID, and ONGENTYS. The Biosciences portfolio includes biosimilar products FYLNETRA, ALYMSYS, Boncresa, and Oziltus, along with specialty injectables like Boruzu and PEMRYDI RTU. The company delivers over 160 million prescriptions annually across the U.S. market.

Differentiator

Problem solved

Functional benefit

Brands

  • Amneal Biosciences: Delivers growing portfolio of biosimilars and specialty injectable products
  • AvKARE
  • CREXONT
  • Brekiya
  • PATHways
  • Boruzu
  • UNITHROID
  • RYTARY
  • ONGENTYS
  • EMVERM
  • ALYMSYS
  • FYLNETRA

Products and services

  • CREXONT (carbidopa and levodopa) Innovative extended-release oral formulation for Parkinson's disease combining immediate-release granules for rapid onset with extended-release pellets for long-lasting efficacy, providing longer Good On time with less frequent dosing.
  • Brekiya (dihydroergotamine mesylate) First and only ready-to-use dihydroergotamine (DHE) autoinjector approved for acute treatment of migraine with or without aura and acute treatment of cluster headaches in adults.
  • RYTARY (carbidopa and levodopa) Extended-release capsules for treatment of Parkinson's disease, providing continuous levodopa delivery.
  • ONGENTYS (opicapone) Capsules for treatment of Parkinson's disease as adjunct therapy to levodopa/carbidopa.
  • UNITHROID (levothyroxine sodium) Oral prescription medicine for hypothyroidism, providing thyroid hormone replacement.
  • EMVERM (mebendazole) Anthelmintic medication for treatment of worm infections including whipworm, hookworm, and pinworm.
  • FYLBAR (filgrastim biosimilar) Biosimilar referencing Neupogen for chemotherapy-induced neutropenia support.
  • FYLNETRA (pegfilgrastim biosimilar) Biosimilar to Amgen's Neulasta for reducing infection incidence in patients receiving myelosuppressive chemotherapy.
  • ALYMSYS (bevacizumab biosimilar) Biosimilar referencing Avastin for treatment of various cancers including metastatic colorectal cancer, non-small cell lung cancer, and renal cell carcinoma.
  • Boncresa (denosumab biosimilar) Biosimilar referencing Amgen's Prolia for osteoporosis treatment and bone loss prevention.
  • Oziltus (denosumab biosimilar) Biosimilar referencing Amgen's XGEVA for prevention of skeletal-related events in cancer patients with bone metastases.
  • Boruzu (generic bortezomib) Generic oncology injectable product for multiple myeloma treatment.
  • PEMRYDI RTU Ready-to-use oncology injectable developed via 505(b)(2) pathway, designed to simplify storage and preparation.
  • Beclomethasone Dipropionate HFA Inhalation Aerosol FDA-approved generic equivalent for QVAR, available in 40 mcg and 80 mcg doses for asthma maintenance therapy in patients 5 years and older.
  • Epinephrine Auto-injector Auto-injector for emergency treatment of anaphylaxis.
  • Naloxone HCl Nasal Spray Opioid overdose reversal medication.
  • Albuterol Sulfate Inhalation Aerosol Generic version of PROAIR HFA for treatment of bronchospasm.
  • Cyclosporine Ophthalmic Emulsion 0.05% Generic version of RESTASIS for dry eye disease by increasing tear production.
  • Iohexol Injection Contrast agent for various imaging procedures including CT scans.
  • Romidepsin Injection Ready-to-use formulation for treating cutaneous T-cell lymphoma in adults who have received at least one prior systemic therapy.
  • PATHways Patient Support Program Comprehensive patient and provider support program offering co-pay assistance, patient assistance, and treatment access support services.
  • AvKARE Distribution Services Distributor of pharmaceuticals and other products for U.S. federal government, retail, and institutional markets.

Quantifiable outcome

  • 160+ million prescriptions delivered annually
  • +3 more outcomes

Companies that use Amneal Pharmaceuticals

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Amneal Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Amneal Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship, strategic and core.

  • Kashiv BioSciencesflagshipStrategic or Co-development Partner · 22 April 2026Definitive agreement for Amneal to acquire Kashiv BioSciences for $375M cash, $375M equity at closing, plus up to $350M in milestones (total $1.1B). The acquisition creates a fully integrated global biosimilars platform combining Kashiv's R&D, manufacturing, and regulatory capabilities with Amneal's commercial scale. Expected to close H2 2026 pending shareholder and regulatory approvals.
  • KeifeRxstrategicStrategic or Co-development Partner · 9 January 2026Research collaboration and option agreement to advance pre-IND development of KFRX06, a preclinical candidate targeting Parkinson's disease based on KeifeRx's LRRK2 inhibitor technology. Collaboration establishes a structured path for potential next-stage development and commercialization.
  • mAbxiencecoreStrategic or Co-development Partner · 22 December 2025Partnership for development and manufacturing of biosimilars. Amneal holds exclusive U.S. commercialization rights for jointly developed biosimilars including Boncresa and Oziltus (denosumab biosimilars referencing Prolia and XGEVA). mAbxience handles development and manufacturing while Amneal commercializes in the U.S.
  • Saol TherapeuticsstrategicStrategic or Co-development Partner · 5 January 2022Acquisition of Saol Therapeutics' Baclofen franchise including Lioresal and LYVISPAH products valued at approximately $83.5 million. Transaction aimed to expand Amneal's neurology portfolio and enhance biosimilar market entry.
  • Puniska HealthcarestrategicStrategic or Co-development Partner · 10 November 2021Acquisition of Indian injectable drug manufacturer Puniska Healthcare for Rs 700 crore. Transaction expanded Amneal's injectable manufacturing capacity in the U.S. and globally, including India. Facility in Ahmedabad was prepared for USFDA inspection.
  • Dispensary of HopecoreStrategic or Co-development PartnerTwelve-year partnership with Nashville-based nonprofit distributing medicines to pharmacies and safety-net clinics for low-income, chronically ill patients. Amneal has donated more than 20 million dosages through this partnership, touching hundreds of thousands of lives across the U.S.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Amneal Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Teva Pharmaceutical Industries: Largest U.S. generics manufacturer with a global specialty franchise (CNS, respiratory) and biosimilars pipeline. Direct head-to-head competitor with Amneal in U.S. generics and CNS specialty, including Parkinson's disease products; Amneal's former CCO (Andy Boyer) and Chief Legal Officer (Jason Daly) both came from Teva, underscoring competitive overlap.
  • Viatris: Global generics and specialty pharma formed from Mylan and Upjohn. Competes directly with Amneal across U.S. generics, biosimilars, and select specialty categories, and is similarly exposed to U.S. generic pricing pressure and biosimilar launch cycles.
  • Sandoz (Novartis): Global leader in generics and biosimilars, now independent from Novartis. Competes directly with Amneal's Affordable Medicines and Biosciences segments, especially in biosimilars (denosumab, pegfilgrastim, bevacizumab) where Amneal is also launching. Jeff George (Amneal director) was previously CEO of Sandoz.
  • Hikma Pharmaceuticals: U.S./MENA generics and injectables manufacturer with a growing specialty franchise. Overlaps with Amneal's generics, injectables, and increasingly specialty footprint, including respiratory and CNS categories.
  • Dr. Reddy's Laboratories: India-based global generics and biosimilars company with substantial U.S. presence. Competes with Amneal in complex generics, injectables, and biosimilars and shares a similar India-plus-US manufacturing cost structure.
  • Sun Pharmaceutical Industries: India's largest specialty pharma company with a significant U.S. generics and specialty business (including CNS). Overlaps directly with Amneal's generic portfolio and U.S. specialty ambitions, particularly in neurology.
  • Aurobindo Pharma: Indian-headquartered global generics and biosimilars manufacturer with strong U.S. share. Competes with Amneal across oral solids, injectables, and biosimilars, including respiratory and CNS categories.
  • Lupin Pharmaceuticals: India-based global pharma with a U.S. generics and specialty franchise (CNS, respiratory, women's health). Direct competitor with Amneal in U.S. complex generics and emerging biosimilars.

Emerging players

  • Endo International: U.S. specialty and generics pharma with focus on neurology, pain, and ophthalmology. Overlaps with Amneal's specialty portfolio in CNS/neurology and shares exposure to U.S. specialty launch dynamics.

Regional players

  • Zydus Lifesciences: India-based pharma with U.S. generics, injectables, and biosimilars business. Comparable to Amneal in manufacturing footprint and product mix; competes most directly in U.S. generics and biosimilars and shares similar India supply-chain dynamics. Several Amneal R&D and quality leaders previously worked at Zydus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Amneal Pharmaceuticals social profiles

Digital presence

Amneal Pharmaceuticals compliance and trust

Trust signal

Compliance1 record

Amneal Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amneal Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles23 records

Amneal Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Amneal Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amneal Pharmaceuticals M&A and investment

M&A and investment

M&A7 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amneal Pharmaceuticals

What does Amneal Pharmaceuticals do?

Amneal Pharmaceuticals develops, manufactures, and commercializes generic pharmaceuticals, specialty branded medicines, and biosimilars across three segments: Affordable Medicines (complex generics, injectables, ophthalmics, inhalation products), Specialty (CNS and endocrine branded therapies for Parkinson's disease, migraine, cluster headache, and hypothyroidism), and AvKARE (pharmaceutical distribution to U.S. federal government, retail, and institutional markets). The company operates approximately 1 million square feet of advanced U.S. manufacturing space and delivers over 160 million prescriptions annually across its 290+ product portfolio.

Is Amneal Pharmaceuticals a public or private company?

Amneal Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Amneal Pharmaceuticals founded?

Amneal Pharmaceuticals was founded in 2002. It employs 5,001 to 10,000 people.

Where is Amneal Pharmaceuticals based?

Amneal Pharmaceuticals is headquartered in Bridgewater, United States, in the North America region.

How does Amneal Pharmaceuticals make money?

Three revenue lines are on record. Affordable Medicines Segment is the primary driver. The others are specialty Segment and avKARE Segment.

Who are Amneal Pharmaceuticals's main competitors?

Direct peers on record are Teva Pharmaceutical Industries, Viatris, Sandoz (Novartis), Hikma Pharmaceuticals, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Aurobindo Pharma and Lupin Pharmaceuticals. Endo International is listed as an emerging player. Zydus Lifesciences is listed as a regional player.

Does Amneal Pharmaceuticals have an API?

No public API is recorded for Amneal Pharmaceuticals.

What industry is Amneal Pharmaceuticals in?

Amneal Pharmaceuticals's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comAmneal Pharmaceuticals stock hits 52-week high at 22.07 USDAmneal Pharmaceuticals stock reached a 52-week high of $22.07, boosting market cap to $7.64 billion. The company reported Q3 2026 adjusted EPS of $0.26, beating estimates, with revenue of $862.7 million. Piper Sandler reiterated an Overweight rating with a $21.00 price target.TradingViewAmneal Pharmaceuticals, Inc. (AMRX) Wins EU Approval for Adcomfo BiosimilarThe European Commission granted marketing authorization for Amneal's Adcomfo biosimilar to XOLAIR, following a confirmatory study of 600 patients that met its primary efficacy endpoint. The UK MHRA had authorized the product in March 2026, and the U.S. application remains under FDA review.Yahoo3 Insider Backed Growth Stocks With At Least 40% Earnings GrowthThree US growth stocks with high insider ownership and at least 40% earnings growth are highlighted: Nebius Group, Cerebras Systems, and Amneal Pharmaceuticals. Nebius and Cerebras focus on AI infrastructure, while Amneal targets complex generics. The article notes timing risks in converting capacity to paid usage.Seeking AlphaAmneal: Buy More After Impressive Q3 Results, As Active Drug Pipeline Keeps GrowingAmneal Pharmaceuticals received a buy reaffirmation after reporting a fourth consecutive earnings beat, with Q3 revenue up 10% and higher FY26 guidance. The company cites a robust pipeline, niche demand, and improving margins, while elevated leverage and integration risks temper the thesis.Simply Wall StAmneal Pharmaceuticals (AMRX) Lifted 2026 Guidance, Is It Still 12% Undervalued?Amneal Pharmaceuticals raised its 2026 net revenue outlook, reporting higher Q3 and YTD sales, a quarterly net loss, and lower impairment charges. At $21.38, the stock trades below its fair value of $24.29, but a P/E of 55.9x signals valuation risk. Management targets an additional $1-2B in Affordable Medicines revenue by 2030.American Banking and Market NewsAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded Amneal Pharmaceuticals from strong-buy to buy. The company reported Q3 EPS of $0.26, beating estimates of $0.23, with revenue of $862.68 million. Analysts have an average rating of Moderate Buy with a $23.00 target.NasdaqShow Me The Money: After A 120% Rally, Amneal (AMRX) Positions For Its Next Growth Chapter In 2027Amneal Pharmaceuticals shares hit a 52-week high of $22.07, up 129% from the publication price, after a 120% rally. The company raised its 2026 revenue guidance to $3.15–3.25 billion and expects 2027 growth from new product launches and the Kashiv BioSciences integration.BioSpaceBioSpace 2027 Best Places to Work shines light on most admired employersBioSpace's 2027 Best Places to Work list honors life sciences employers with U.S. operations, with Amneal Pharmaceuticals ranking first among large employers and BridgeBio first among small employers. The list is based on input from over 8,200 biopharma professionals, with nominations in June and voting through August.YahooTop 3 Insider Owned Growth Stocks To Watch In November 2026Three high-growth, high-insider-ownership stocks—Pinterest, Reformation, and Amneal Pharmaceuticals—are profiled with operations and market cap figures. Pinterest's monetization gap, Reformation's store expansion, and Amneal's generics-to-specialty shift are highlighted as key drivers. The article notes these are general ideas, not financial advice.Simply Wall StAmneal Pharmaceuticals (AMRX) Lifts 2026 Guidance, Is The 12% Undervalued View Enough?Amneal Pharmaceuticals raised its full-year 2026 revenue outlook despite a mixed quarter with higher sales, a net loss, and impairment charges. Analysts see the stock undervalued at $23 versus $20.14, citing a shift toward complex generics and a target of $1-2 billion in Affordable Medicines revenue by 2030.